Search Results
Mar 30, 2026, 09:05 ET INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Mar 30, 2026, 03:47 ET Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of INO during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 30, 2026, 03:46 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 29, 2026, 08:52 ET INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 26, 2026, 15:49 ET Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Law Offices of Howard G. Smith
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Mar 25, 2026, 16:57 ET Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Mar 25, 2026, 09:00 ET Inovio Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Inovio Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2026 - INO
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: Levi & Korsinsky, LLP
Mar 24, 2026, 09:00 ET INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm
Mar 23, 2026, 18:50 ET INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Mar 22, 2026, 09:04 ET INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 19, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Mar 18, 2026, 18:12 ET INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Mar 18, 2026, 09:00 ET LEVI & KORSINSKY, LLP: APRIL 7, 2026 -- DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION
/PRNewswire/ -- IMPORTANT DATE: April 7, 2026. Investors who wish to seek appointment as lead plaintiff in the Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities class action must file a motion by this date. Missing the deadline means forfeiting the opportunity to direct the litigation and select lead
More news about: Levi & Korsinsky, LLP
Mar 17, 2026, 16:30 ET KD SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Kyndryl (KD) Investors of Securities Class Action Deadline on April 13, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 16:25 ET INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 16:00 ET INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 09:00 ET INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm
Mar 16, 2026, 16:25 ET Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Glancy Prongay Wolke & Rotter LLP
Mar 12, 2026, 16:32 ET Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Mar 12, 2026, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Record, specialty distributor, specialty pharmacy, and patient HUB.INO-5412/INO-5401INOVIO announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class
More news about: INOVIO Pharmaceuticals, Inc.
Mar 12, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Mar 11, 2026, 16:47 ET Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Law Offices of Howard G. Smith
Mar 11, 2026, 09:20 ET INO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Mar 10, 2026, 09:00 ET Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm